WO2017052355A3 - Use of peptide drugs for the treatment of osteoporosis and for bone regeneration - Google Patents
Use of peptide drugs for the treatment of osteoporosis and for bone regeneration Download PDFInfo
- Publication number
- WO2017052355A3 WO2017052355A3 PCT/MX2016/000093 MX2016000093W WO2017052355A3 WO 2017052355 A3 WO2017052355 A3 WO 2017052355A3 MX 2016000093 W MX2016000093 W MX 2016000093W WO 2017052355 A3 WO2017052355 A3 WO 2017052355A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteoporosis
- treatment
- peptides
- bone regeneration
- peptide drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides osteogenic peptides derived from cementum attachment protein (HACD1/CAP) and another derived from cementum protein 1 (CEMP1), and pharmaceutical compositions of said peptides for the prevention and treatment of osteopenia and osteoporosis. These peptides increased bone mineral density in an osteoporotic model, without side effects in vivo, demonstrating clinical effectiveness in the prevention and treatment of osteopenia and osteoporosis in vivo, as well as in bone repair and/or regeneration.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/865,909 US20170088584A1 (en) | 2015-09-25 | 2015-09-25 | Use of peptidic drugs for osteoporosis treatment and bone regeneration |
US14/865,909 | 2015-09-25 | ||
MX2015016238A MX369939B (en) | 2015-09-25 | 2015-11-25 | Use of peptidic drugs for osteoporosis treatment and bone regeneration. |
MXMX/A/2015/016238 | 2015-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017052355A2 WO2017052355A2 (en) | 2017-03-30 |
WO2017052355A3 true WO2017052355A3 (en) | 2017-05-26 |
Family
ID=58386544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2016/000093 WO2017052355A2 (en) | 2015-09-25 | 2016-09-26 | Use of peptide drugs for the treatment of osteoporosis and for bone regeneration |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017052355A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009013369A (en) * | 2009-12-08 | 2011-06-15 | Univ Mexico Nacional Autonoma | Tissue engineering for the formation of radicular cementum, bone, dentine, cartilage and periodontal ligament by using human cementum protein 1 (cemp-1). |
MX2012005314A (en) * | 2012-05-07 | 2013-11-27 | Univ Mexico Nacional Autonoma | Biologically active peptide for repairing and regenerating bone. |
-
2016
- 2016-09-26 WO PCT/MX2016/000093 patent/WO2017052355A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009013369A (en) * | 2009-12-08 | 2011-06-15 | Univ Mexico Nacional Autonoma | Tissue engineering for the formation of radicular cementum, bone, dentine, cartilage and periodontal ligament by using human cementum protein 1 (cemp-1). |
MX2012005314A (en) * | 2012-05-07 | 2013-11-27 | Univ Mexico Nacional Autonoma | Biologically active peptide for repairing and regenerating bone. |
Non-Patent Citations (4)
Title |
---|
ALVAREZ-PÉREZ, MARCO ANTONIO ET AL.: "Molecular cloning, expression and immunolocalization of a novel human cementum-derived protein (CP-23).", BONE, vol. 38, no. 3, 2006, pages 409 - 414 and 417-418, XP027908126 * |
CARMONA-RODRÍGUEZ, BRUNO ET AL.: "Human Cementum Protein 1 induces expression of bone and cementum proteins by human gingival fibroblasts.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 358, no. 3, 2007, pages 763 - 769, XP025322371 * |
PRIEGO, ADRIANA RIVERA; ET AL.: "Producción and caracterización de una proteína recombinante del cemento (CEMP 1) en células de Drosophila melanogaster (DML-2-23).", REVISTA ODONTOLÓGICA MEXICAN A, vol. 17, no. 2, 2013, pages 76 - 80, XP055384163 * |
VILLARREAL-RAMÍREZ, EDUARDO ET AL.: "Characterization of recombinant human cementum protein 1 (hrCEMP1): primary role in biomineralization.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 384, no. 1, 2009, pages 49 - 54, XP026115673 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017052355A2 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005291A (en) | Vaccines for treatment and prevention of cancer. | |
MX2020011333A (en) | Therapeutic use of bone morphogenetic proteins. | |
WO2016170348A3 (en) | Sarna compositions and methods of use | |
MX2019000588A (en) | Somatostatin modulators and uses thereof. | |
WO2016060996A3 (en) | Interleukin-15 compositions and uses thereof | |
WO2017020034A8 (en) | Use of c-type natriuretic peptide variants to treat skeletal dysplasia | |
MX2019010949A (en) | Somatostatin modulators and uses thereof. | |
WO2017023933A3 (en) | Peptidomimetic macrocycles | |
MX2016012262A (en) | Cenicriviroc for the treatment of fibrosis. | |
IL286592B (en) | Amino acid compositions for the treatment of liver disease | |
WO2013186777A3 (en) | Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases | |
WO2016100619A3 (en) | Treatment and diagnosis of cancer | |
MX2019003805A (en) | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies. | |
WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
PH12017501070A1 (en) | Peptides and their use in the treatment of skin | |
WO2016193872A3 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
MA39342A1 (en) | Antibodies il -21 | |
MX2017016227A (en) | Broad-spectrum anti-infective peptides. | |
MX2022013283A (en) | Compositions for colon cleansing and the treatment of gastrointestinal disorders. | |
BR112016023519A2 (en) | wnt / ß-catenin signaling inhibitor, pharmaceutical composition and method of treating and / or preventing a pathology defined by vascular malformation | |
MX2017010277A (en) | Cenicriviroc for the treatment of fibrosis. | |
EP3626712A3 (en) | Liver x receptor (lxr) modulators | |
PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
MX2015016238A (en) | Use of peptidic drugs for osteoporosis treatment and bone regeneration. | |
WO2016011201A3 (en) | Epha4 cyclic peptide antagonists for neuroprotection and neural repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16849079 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16849079 Country of ref document: EP Kind code of ref document: A2 |